Article metrics

Download PDFPDF

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

 

Online download statistics by month:

Online download statistics by month: February 2019 to May 2024

AbstractFullPdf
Feb 2019848019
Mar 2019757122
Apr 2019414027
May 2019353520
Jun 2019201916
Jul 201910107
Aug 201917174
Sep 2019202013
Oct 201915167
Nov 201917145
Dec 2019883
Jan 2020995
Feb 202022224
Mar 202020188
Apr 202013132
May 202011112
Jun 202014146
Jul 20201491495
Aug 2020977
Sep 202015114
Oct 202022228
Nov 202010102
Dec 2020663
Jan 2021663
Feb 2021554
Mar 2021557
Apr 202113138
May 202112126
Jun 202112122
Jul 202110107
Aug 2021141412
Sep 2021556
Oct 202191019
Nov 2021131318
Dec 2021885
Jan 2022784
Feb 202214158
Mar 2022773
Apr 202210109
May 202222229
Jun 202226266
Jul 202211112
Aug 202227278
Sep 2022282813
Oct 202219198
Nov 2022171711
Dec 2022443
Jan 202381212
Feb 202320203
Mar 2023788
Apr 2023885
May 2023448
Jun 2023442
Jul 2023555
Aug 2023335
Sep 2023551
Oct 2023662
Nov 202313143
Dec 2023661
Jan 2024442
Feb 2024994
Mar 20248827
Apr 20241094
May 202410115
Total10761065477